JP7149285B2 - Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物 - Google Patents

Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物 Download PDF

Info

Publication number
JP7149285B2
JP7149285B2 JP2019550687A JP2019550687A JP7149285B2 JP 7149285 B2 JP7149285 B2 JP 7149285B2 JP 2019550687 A JP2019550687 A JP 2019550687A JP 2019550687 A JP2019550687 A JP 2019550687A JP 7149285 B2 JP7149285 B2 JP 7149285B2
Authority
JP
Japan
Prior art keywords
toxin
immunogenic polypeptide
multivalent immunogenic
protein
fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019550687A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020509770A (ja
JP2020509770A5 (OSRAM
Inventor
ティアン，ジン－フイ
リウ，イエ
スミス，ゲイル
グレン，グレゴリー
フライヤー，デイビッド
Original Assignee
ノババックス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノババックス，インコーポレイテッド filed Critical ノババックス，インコーポレイテッド
Publication of JP2020509770A publication Critical patent/JP2020509770A/ja
Publication of JP2020509770A5 publication Critical patent/JP2020509770A5/ja
Priority to JP2022153071A priority Critical patent/JP7397145B2/ja
Application granted granted Critical
Publication of JP7149285B2 publication Critical patent/JP7149285B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019550687A 2017-03-15 2018-03-15 Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物 Active JP7149285B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022153071A JP7397145B2 (ja) 2017-03-15 2022-09-26 Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762471636P 2017-03-15 2017-03-15
US62/471,636 2017-03-15
US201762474434P 2017-03-21 2017-03-21
US62/474,434 2017-03-21
PCT/US2018/022597 WO2018170238A2 (en) 2017-03-15 2018-03-15 Methods and compositions for inducing immune responses against clostridium difficile

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022153071A Division JP7397145B2 (ja) 2017-03-15 2022-09-26 Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2020509770A JP2020509770A (ja) 2020-04-02
JP2020509770A5 JP2020509770A5 (OSRAM) 2021-04-22
JP7149285B2 true JP7149285B2 (ja) 2022-10-06

Family

ID=63523217

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019550687A Active JP7149285B2 (ja) 2017-03-15 2018-03-15 Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物
JP2022153071A Active JP7397145B2 (ja) 2017-03-15 2022-09-26 Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022153071A Active JP7397145B2 (ja) 2017-03-15 2022-09-26 Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物

Country Status (12)

Country Link
US (2) US11123419B2 (OSRAM)
EP (1) EP3595709A4 (OSRAM)
JP (2) JP7149285B2 (OSRAM)
KR (1) KR102640722B1 (OSRAM)
CN (1) CN110691609B (OSRAM)
AU (1) AU2018236352B2 (OSRAM)
BR (1) BR112019019117A2 (OSRAM)
CA (1) CA3056090A1 (OSRAM)
IL (1) IL269258B2 (OSRAM)
MX (1) MX2019010948A (OSRAM)
SG (1) SG11201908376UA (OSRAM)
WO (1) WO2018170238A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022179543A (ja) * 2017-03-15 2022-12-02 ノババックス，インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047085T2 (hu) 2011-04-22 2020-04-28 Wyeth Llc Clostridium difficile mutáns toxinjához kapcsolódó készítmények és eljárásai
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
EP4168032A2 (en) * 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017383A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
WO2011060431A2 (en) 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
JP2014530010A (ja) 2011-09-30 2014-11-17 ノババックス，インコーポレイテッド 呼吸器合胞体ウイルス用の組み換えナノ粒子ｒｓｖｆワクチン
JP2015506948A (ja) 2012-01-27 2015-03-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 組換え毒素を含むクロストリジウム・ディフィシレに対するワクチン
WO2015197737A1 (en) 2014-06-25 2015-12-30 Glaxosmithkline Biologicals S.A. Clostridium difficile immunogenic composition
JP2016502551A (ja) 2012-12-05 2016-01-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
JP2016504993A (ja) 2012-12-23 2016-02-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃ．ディフィシルＣＤＴｂ及び／又はＣＤＴａタンパク質のエレメントを含む免疫原性組成物
JP2016518374A (ja) 2013-04-22 2016-06-23 ボード オブ リージェンツ オブ ザ ユニバーシテイ オブ オクラホマ クロストリジウム・ディフィシルワクチン及び使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
JP2002509943A (ja) * 1997-09-04 2002-04-02 イーストマン ケミカル カンパニー 固相重合速度を高める熱可塑性ポリウレタン添加剤
US20130039973A1 (en) * 2011-08-03 2013-02-14 Henry J. Smith Viral Immunogenic Compositions
WO2015063647A1 (en) * 2013-11-01 2015-05-07 Pfizer Inc. Vectors for expression of prostate-associated antigens
CN106220737B (zh) * 2016-07-21 2020-11-10 中国人民解放军军事医学科学院微生物流行病研究所 融合蛋白及其在治疗艰难梭菌相关疾病中的应用
CA3056090A1 (en) 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017383A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
WO2011060431A2 (en) 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
JP2014530010A (ja) 2011-09-30 2014-11-17 ノババックス，インコーポレイテッド 呼吸器合胞体ウイルス用の組み換えナノ粒子ｒｓｖｆワクチン
JP2015506948A (ja) 2012-01-27 2015-03-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 組換え毒素を含むクロストリジウム・ディフィシレに対するワクチン
JP2016502551A (ja) 2012-12-05 2016-01-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
JP2016504993A (ja) 2012-12-23 2016-02-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃ．ディフィシルＣＤＴｂ及び／又はＣＤＴａタンパク質のエレメントを含む免疫原性組成物
JP2016518374A (ja) 2013-04-22 2016-06-23 ボード オブ リージェンツ オブ ザ ユニバーシテイ オブ オクラホマ クロストリジウム・ディフィシルワクチン及び使用方法
WO2015197737A1 (en) 2014-06-25 2015-12-30 Glaxosmithkline Biologicals S.A. Clostridium difficile immunogenic composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Infection and Immunity, 2016, Vol.84, No.1, pp.194-204

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022179543A (ja) * 2017-03-15 2022-12-02 ノババックス，インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物
JP7397145B2 (ja) 2017-03-15 2023-12-12 ノババックス，インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物

Also Published As

Publication number Publication date
JP7397145B2 (ja) 2023-12-12
IL269258A (en) 2019-11-28
SG11201908376UA (en) 2019-10-30
BR112019019117A2 (pt) 2020-05-05
US11123419B2 (en) 2021-09-21
JP2022179543A (ja) 2022-12-02
US20220211834A1 (en) 2022-07-07
US20200085934A1 (en) 2020-03-19
US11938179B2 (en) 2024-03-26
IL269258B1 (en) 2023-05-01
WO2018170238A2 (en) 2018-09-20
CA3056090A1 (en) 2018-09-20
KR102640722B1 (ko) 2024-02-26
WO2018170238A3 (en) 2018-10-18
CN110691609B (zh) 2024-04-19
EP3595709A4 (en) 2020-12-23
KR20190125470A (ko) 2019-11-06
CN110691609A (zh) 2020-01-14
JP2020509770A (ja) 2020-04-02
IL269258B2 (en) 2023-09-01
AU2018236352A1 (en) 2019-10-03
MX2019010948A (es) 2020-01-09
EP3595709A2 (en) 2020-01-22
RU2019132111A3 (OSRAM) 2021-06-29
RU2019132111A (ru) 2021-04-15
AU2018236352B2 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
JP7397145B2 (ja) Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅに対する免疫応答を誘導するための方法および組成物
US8986704B2 (en) Mutant fragments of OspA and methods and uses relating thereto
CN114617959A (zh) 具有改进的稳定性和免疫原性的疫苗组合物
CN103154242A (zh) 诺如病毒衍生的免疫原性组合物和方法
CN101605558A (zh) 流感重组亚单位疫苗
KR102041032B1 (ko) 돼지 생식기 호흡기 증후군 및 돼지 써코바이러스 연관 질환에 대한 백신 조성물
JP2013520487A (ja) 免疫原性タンパク質および組成物
KR101919002B1 (ko) 구제역 바이러스의 가용성 다가 항원단백질 및 이의 용도
JP2012532626A (ja) 無毒化されたＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原
WO2007125535A1 (en) Recombinant flagellin gene and uses thereof
US11136354B2 (en) Protective anti-ZIKV vaccine without inducing cross-reactions with dengue
KR20120131725A (ko) 고병원성 조류인플루엔자 ａ ｈ５ｎ１ 바이러스 유사입자 및 이를 이용한 가금용 백신
RU2781057C9 (ru) Способы и композиции для индукции иммунного ответа против clostridium difficile
RU2781057C2 (ru) Способы и композиции для индукции иммунного ответа против clostridium difficile
US9493518B2 (en) Compositions and methods for treating clostridium difficile-associated diseases
US20240197865A1 (en) Compositions and methods for preventing rsv and piv3 infections
HK40075643A (en) Vaccine compositions with improved stability and immunogenicity
HK40075644A (en) Vaccine compositions with improved stability and immunogenicity
WO2023015262A2 (en) Glycoengineered foldon domains and related compositions and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210310

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220803

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220926

R150 Certificate of patent or registration of utility model

Ref document number: 7149285

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250